Form 4: Elicio Therapeutics Director Julian Adams Acquires Stock Options

Director Julian Adams acquired stock options for 7,900 shares of Elicio Therapeutics common stock on May 19, 2025.

Summary

• On May 19, 2025, Julian Adams, a director of Elicio Therapeutics, acquired stock options representing the right to buy 7,900 shares of common stock.
• The exercise price of these options is $5.84 per share.
• The options vest fully on the earlier of May 19, 2026, or the next annual meeting of the Company's stockholders after the grant date, contingent upon continued service to the Issuer.
• The options expire on May 19, 2035.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, so the sentiment is neither positive nor negative.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the holdings and transactions of company directors. It's a standard practice for publicly traded companies.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

Elicio Therapeutics, Director, Stock Options, Form 4, Beneficial Ownership, ELTX, Securities